Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDP173
- Development stage
- Preclinical
- Lead developer
- EddingGenor Pharmaceutical Group
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
EDP173 is an investigational dual-targeting small interfering RNA (siRNA) therapeutic developed by Genor Biopharma for the treatment of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD). As part of Genor's oligonucleotide platform, EDP173 is designed to simultaneously silence two distinct mRNA targets involved in lipid metabolism. By inhibiting the expression of these targets, the drug aims to lower plasma lipid levels and reduce the risk of cardiovascular events associated with ASCVD. The specific biological targets of EDP173 have not been publicly disclosed, but the candidate is part of a broader cardiometabolic pipeline that includes other dual-targeting siRNAs and antisense oligonucleotides.
Beyond the preview
Go deeper on EDP173.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDP173.